Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

被引:155
作者
Kinoshita, Yoshikazu [1 ]
Ishimura, Norihisa [1 ]
Ishihara, Shunji [1 ]
机构
[1] Shimane Univ, Sch Med, Dept Gastroenterol & Hepatol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan
基金
日本学术振兴会;
关键词
Adverse effect; Allergic disease; Gastric acid; Gastroesophageal reflux; Ulcer; SPONTANEOUS BACTERIAL PERITONITIS; COMPETITIVE ACID BLOCKER; GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; COMMUNITY-ACQUIRED PNEUMONIA; BONE-MINERAL DENSITY; CLOSTRIDIUM-DIFFICILE INFECTION; ACUTE INTERSTITIAL NEPHRITIS; DUAL ANTIPLATELET THERAPY; CLINICAL-OUTCOMES;
D O I
10.5056/jnm18001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Proton pump inhibitors (PPIs) potently inhibit gastric acid secretion and are widely used for treatment of acid-related diseases including gastroesophagealre flux disease and secondary prevention of aspirin/NSAID-induced ulcers. Although clinically important adverse effects of PPIs can occur, just as with other drugs, those are not frequently observed during or after administration. Thus, PPIs are regarded as relatively safe and considered to be clinically beneficial. Recently, PPIs have become frequently administered to patients with functional gastrointestinal diseases or primary prevention of drug-related gastroduodenal damage, even though their beneficial effects for those conditions have not been fully confirmed. PPIs tend to be given for conditions in which the necessity of the drug has not been clarified, thus otherwise rare adverse effects are presented as clinically relevant. Although several PPI-related adverse effects have been reported, their clinical relevance is not yet clear, since the evidence reported in those studies is not at a high enough level, as the majority are based on retrospective observational studies and the reported hazard ratios are low. It is important to administer PPIs only for patients who will gain a substantial clinical benefit and to continue to investigate their adverse effects with high quality prospective studies.
引用
收藏
页码:182 / 196
页数:15
相关论文
共 155 条
[1]   CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole [J].
Adachi, K ;
Katsube, T ;
Kawamura, A ;
Takashima, T ;
Yuki, M ;
Amano, K ;
Ishihara, S ;
Fukuda, R ;
Watanabe, M ;
Kinoshita, Y .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1259-1266
[2]   Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine [J].
Adachi, K ;
Komazawa, Y ;
Mihara, T ;
Azumi, T ;
Fujisawa, T ;
Katsube, T ;
Furuta, K ;
Kinoshita, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (07) :1012-1015
[3]   Chronic Proton Pump Inhibitor Therapy Associated with Increased Development of Fundic Gland Polyps [J].
Ally, Mazer R. ;
Veerappan, Ganesh R. ;
Maydonovitch, Corinne L. ;
Duncan, Timothy J. ;
Perry, Joseph L. ;
Osgard, Eric M. ;
Wong, Roy K. H. .
DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (12) :2617-2622
[4]   Proton pump inhibitors are associated with increased risk of development of chronic kidney disease [J].
Arora, Pradeep ;
Gupta, Anu ;
Golzy, Mojgan ;
Patel, Nilang ;
Carter, Randolph L. ;
Jalal, Kabir ;
Lohr, James W. .
BMC Nephrology, 2016, 17
[5]   Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis [J].
Ashida, K. ;
Sakurai, Y. ;
Hori, T. ;
Kudou, K. ;
Nishimura, A. ;
Hiramatsu, N. ;
Umegaki, E. ;
Iwakiri, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) :240-251
[6]   Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies [J].
Attwood, S. E. ;
Ell, C. ;
Galmiche, J. P. ;
Fiocca, R. ;
Hatlebakk, J. G. ;
Hasselgren, B. ;
Langstrom, G. ;
Jahreskog, M. ;
Eklund, S. ;
Lind, T. ;
Lundell, L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (11) :1162-1174
[7]   The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production [J].
Badiola, Nahuai ;
Alcalde, Victor ;
Pujol, Albert ;
Muenter, Lisa-Marie ;
Multhaup, Gerd ;
Lleo, Alberto ;
Coma, Mireia ;
Soler-Lopez, Montserrat ;
Aloy, Patrick .
PLOS ONE, 2013, 8 (03)
[8]   Modeling and Simulation of the Effect of Proton Pump Inhibitors on Magnesium Homeostasis. 1. Oral Absorption of Magnesium [J].
Bai, Jane P. F. ;
Hausman, Ethan ;
Lionberger, Robert ;
Zhang, Xinyuan .
MOLECULAR PHARMACEUTICS, 2012, 9 (12) :3495-3505
[9]   Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection [J].
Bavishi, C. ;
DuPont, H. L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (11-12) :1269-1281
[10]   Omeprazole-induced acute interstitial nephritis: A possible Th1-Th17-mediated injury? [J].
Berney-Meyer, Linda ;
Hung, Noelyn ;
Slatter, Tania ;
Schollum, John B. W. ;
Kitching, A. Richard ;
Walker, Robert J. .
NEPHROLOGY, 2014, 19 (06) :359-365